Novo Nordisk has once again demonstrated its drive to stay on top in obesity, unveiling its second licensing deal in a matter of days.
Novo Adds Lexicon’s Novel Obesity Drug To Deal Flurry
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
More from Deals
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.
More from Start-Ups & SMEs
• By
The Biovelocita II fund is supported by the likes of Amgen, Bristol Myers Squibb and Pfizer
• By
CEO Adam Steensberg has led a major change in fortunes for the Danish biotech since March 2022.
• By
The Singapore and Seattle-based biotech is joining the race to bring a ‘double whammy’ antibody-drug conjugate to patients.